Latest Carcinoma Stories
Internationally-renowned swimming champion Paul Hutinger says cancer is no match for him ST. PETERSBURG, Fla. (PRWEB) March 07, 2013 When 88-year-old Masters Hall of Fame swimmer and esteemed coach, Paul Hutinger, Ph.D., was diagnosed with squamous cell carcinoma of the nose, the champion took it in “stride.” As an All-American athlete, top exercise physiology researcher, and competitive swimmer, with over 800 top ten achievements and 70 current world records over 72 years, Dr....
Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States. Pinpointing where this cancer originates has been difficult because 70 percent of patients are in advanced stages of disease by the time it is detected. Because the origin of ovarian carcinoma development is unknown, early diagnostic tests have so far been unsuccessful. Some epithelial cancers are known...
A protein involved in the internal cell scaffold is associated with increased risk of metastasis and mortality in a range of common cancers finds a meta-analysis published in Biomed Central's open access journal BMC Medicine. The protein, fascin-1, is involved in bundling together the actin filaments which form the internal scaffolding of a cell and are involved in cell movement. Though it is absent, or only present at a low level in normal epithelial cells, several small studies have...
Nobel Laureate Mario R. Capecchi leads collaboration of researchers Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form. CCS arises in connective soft tissues, such as...
CALGARY, Feb. 8, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment...
PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, "Predicting progression of bladder...
BURLINGTON, Mass., Feb. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the market for squamous cell carcinoma of the head and neck (SCCHN) in the United States and Europe will continue to face a high unmet need for targeted therapies aimed at specific subsets of patients, including those with human papillomavirus (HPV)-positive and Epstein-Barr virus (EBV)-positive...
HIV-positive patients have a higher incidence of non-melanoma skin cancers, according to a Kaiser Permanente study that appears in the current online issue of the Journal of the National Cancer Institute. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive individuals compared to those who are HIV-negative. The study cohort of 6,560 HIV-positive and almost 37,000 HIV-negative subjects was drawn from members of Kaiser Permanente Northern...
BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the treatment landscape for hepatocellular carcinoma in the United States and Europe will change dramatically through 2021 as three new, potentially high priced therapies-Novartis's Afinitor, ArQule's tivantinib and Celsion's ThermoDox-arrive on the market, thereby greatly increasing treatment...
OAKLAND, Calif., Jan. 29, 2013 /PRNewswire/ -- HIV-positive patients have a higher incidence of non-melanoma skin cancers, according to a Kaiser Permanente study that appears in the current online issue of the Journal of the National Cancer Institute. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive individuals compared to those who are HIV-negative. The study cohort of 6,560 HIV-positive and almost 37,000 HIV-negative subjects...
